AbbVie Inc. $ABBV Stock Acquired by Artemis Investment Management LLP

Artemis Investment Management LLP increased its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 3.0% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 497,086 shares of the company’s stock after purchasing an additional 14,495 shares during the quarter. Artemis Investment Management LLP’s holdings in AbbVie were worth $130,033,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. YHB Investment Advisors Inc. grew its stake in AbbVie by 0.3% during the third quarter. YHB Investment Advisors Inc. now owns 37,565 shares of the company’s stock worth $9,827,000 after buying an additional 125 shares during the period. Apella Capital LLC raised its stake in shares of AbbVie by 14.2% in the 3rd quarter. Apella Capital LLC now owns 23,477 shares of the company’s stock valued at $6,371,000 after acquiring an additional 2,912 shares during the period. Everhart Financial Group Inc. raised its stake in shares of AbbVie by 1.8% in the 3rd quarter. Everhart Financial Group Inc. now owns 25,782 shares of the company’s stock valued at $6,744,000 after acquiring an additional 454 shares during the period. Gradient Investments LLC lifted its holdings in shares of AbbVie by 2.1% during the 3rd quarter. Gradient Investments LLC now owns 79,282 shares of the company’s stock valued at $20,739,000 after acquiring an additional 1,634 shares in the last quarter. Finally, Avidian Wealth Enterprises LLC boosted its position in AbbVie by 2.5% during the 3rd quarter. Avidian Wealth Enterprises LLC now owns 36,207 shares of the company’s stock worth $9,471,000 after purchasing an additional 876 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: FDA breakthrough designations strengthen the oncology pipeline. The FDA granted two Breakthrough Therapy Designations for investigational telisotuzumab adizutecan (Temab-A/ABBV-400) in colorectal cancer and non-small cell lung cancer. The designations may accelerate development and regulatory discussions for the company’s next-generation antibody-drug conjugate. AbbVie Temab-A FDA breakthrough designations
• Positive Sentiment: Epkinly produced a significant Phase 3 result. AbbVie and Genmab reported that epcoritamab plus R-CHOP reduced the risk of progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma. The data could support broader adoption and a stronger competitive position against Roche’s Polivy. AbbVie and Genmab Epkinly Phase 3 results
• Positive Sentiment: Analysts remain constructive. Cantor Fitzgerald raised its AbbVie price target to $290 from $285 and maintained an overweight rating. HSBC has also outlined a bullish case with a $315 target, providing additional support for investor sentiment.
• Neutral Sentiment: Broader market factors may be limiting gains. Rising Treasury yields and uncertain equity-market conditions are creating pressure across stocks, even as healthcare companies benefit from defensive characteristics.
• Negative Sentiment: Dividend sustainability remains a concern. Recent commentary highlighted AbbVie’s reported payout ratio near 190%, raising questions about how comfortably earnings cover the dividend. The concern may weigh on income-focused investors, although adjusted earnings and cash flow can differ from reported net income.
• Negative Sentiment: Valuation leaves less room for disappointment. With ABBV trading near its 52-week high and at an elevated earnings multiple, investors may be taking profits or demanding stronger evidence that new medicines can offset long-term Humira-related pressures.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ABBV. Argus increased their price target on AbbVie from $250.00 to $270.00 in a report on Tuesday, August 4th. Wolfe Research raised AbbVie from a “peer perform” rating to an “outperform” rating and upped their target price for the stock from $235.00 to $300.00 in a research report on Thursday, August 13th. Leerink Partners increased their target price on AbbVie from $245.00 to $279.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. Wells Fargo & Company raised their target price on AbbVie from $295.00 to $300.00 and gave the company an “overweight” rating in a report on Monday, August 17th. Finally, Bank of America reissued a “buy” rating on shares of AbbVie in a research report on Tuesday, September 8th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and an average price target of $276.11.

Insider Activity

In related news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.06% of the company’s stock.

AbbVie Stock Performance

Shares of NYSE:ABBV traded down $2.33 during trading on Thursday, hitting $269.03. The company’s stock had a trading volume of 1,665,149 shares, compared to its average volume of 6,408,634. The company has a market capitalization of $475.31 billion, a PE ratio of 76.02, a PEG ratio of 1.22 and a beta of 0.24. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $274.94. The stock’s 50-day moving average price is $258.27 and its two-hundred day moving average price is $235.87.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The firm had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. During the same quarter last year, the firm earned $2.97 EPS. AbbVie’s quarterly revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities analysts predict that AbbVie Inc. will post 13.93 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.6%. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.